Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Its efficacy and safety in improving blood sugar control have led to its approval by the United States Food and Drug Administration (USFDA) in May 2022 for treating T2D
Many individuals find their optimal balance at 0.5mg or 1.0mg and remain there long-term
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about retatrutide as a potential treatment for adults with type 2 diabetes and obesity or overweight and adults with severe obesity and established cardiovascular disease, and the timeline for future readouts, presentations and other milestones relating to retatrutide and its clinical trials and reflects Lilly's current beliefs and expectations
US$ 25.55
US$ 24.00
US$ 27.50
US$ 27.28
US$ 26.09
